1 approved for marketing, 1 completed, 1 unknown. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Monocarboxylate Transporter 8 Deficiency: new trials by email Literature Review of Monocarboxylate Transporter 8 Deficiency trials Research Report on Monocarboxylate Transporter 8 Deficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency) Tiratricol, Placebo - Monocarboxylate Transporter 8 Deficiency, Allan-Herndon-Dudley Syndrome | Phase 3 | Completed | Rare Thyroid Therapeutics International AB | 20 | 2023-07-21 | 2026-04-08 |
| Glycerol-Phenylbutyrate Treatment in Children With MCT Mutation (Allan-Herndon- Dudley Syndrome) Glycerol Phenylbutyrate 1100 MG/ML - Monocarboxylate Transporter 8 Deficiency | Phase 2 / Phase 3 | Unknown | Kaplan Medical Center | 6 | 2021-06-30 | 2021-08-24 |
| Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency Tiratricol - Monocarboxylate Transporter 8 Deficiency, Allan-Herndon-Dudley Syndrome | Approved for marketing | Rare Thyroid Therapeutics International AB | 2026-10-06 |
Allan-Herndon-Dudley syndrome (3)
3,3',5-triiodothyroacetic acid (2) · glycerol phenylbutyrate (1)
Rare Thyroid Therapeutics International AB (2) · Kaplan Medical Center (1)
United States (2) · Israel (1) · Netherlands (1) · United Kingdom (1)
Amnon Zung, MD (1) · Andrew J. Bauer, MD (1) · W. E. Visser, MD (1)